Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report
Oncology Research and Treatment · 2025
DOI: 10.1159/000545975 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Marlies Vornhülz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, LMU Hospital, Munich, Germany, marlies.vornhuelz@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Ataxia Telangiectasia Mutated Proteins, Phthalazines, Piperazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Pancreatic cancer remains a lethal disease with limited therapeutic options. Treatment with PARP inhibitors has been successfully described mainly in patients with germline mutation in BRCA1/2. The efficacy of PARP inhibitors in patients with alterations in other genes in the homologous repair pathway is under discussion. Case Presentation: A 77-year-old male patient with metastatic pancreatic ductal adenocarcinoma (PDAC) was initially treated with 5-fluoruracil, oxaliplatin, and irinotecan, followed by 5-floururacil and irinotecan over the course of 1 year, leading to sustained partial remission. Molecular genetic analysis of the tumor revealed an inactivating R2034Ter mutation in the ataxia telangiectasia serine/threonine kinase gene (ATM), being part of a homologous DNA damage repair pathway eventually involving BRCA1 and BRCA2. After discussion in the molecular tumor board, the patient received off-label olaparib maintenance therapy, under which disease was stable over a period of 18 months. After developing one new liver metastasis at 21 months on olaparib, he received conventional therapy with gemcitabine/cisplatin to which he responded.
Conclusion
This is the first case of an R2034Ter ATM mutant PDAC with sustained clinical response under olaparib maintenance therapy reported. In select cases, ATM, a member of the BRCA pathway, might be a druggable target in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine II, LMU Hospital, Munich, Germany, marlies.vornhuelz@med.uni-muenchen.de.
- Bavarian Cancer Research Center (BZKF), Munich, Germany, marlies.vornhuelz@med.uni-muenchen.de.
- Department of Internal Medicine II, LMU Hospital, Munich, Germany.
- Bavarian Cancer Research Center (BZKF), Munich, Germany.
- Department of Internal Medicine III, LMU Hospital, Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Zitieren
APA
Vornhülz, M., Angelberger, M., Sirtl, S., Philipp, A. B., Rössler, D., Ondrejkova, K., Markwardt, D., Heinrich, K., Westphalen, C. B., Heinemann, V., Jung, A., Rogowski, P., Niyazi, M., Kleger, A., Mayerle, J., Beyer, G., & Beyer, G. (2025). Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Oncology Research and Treatment. https://doi.org/10.1159/000545975
Vancouver
Vornhülz M, Angelberger M, Sirtl S, Philipp AB, Rössler D, Ondrejkova K, et al. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Oncology Research and Treatment. 2025. doi:10.1159/000545975
BibTeX
@article{Vornhlz2025,
author = {Vornhülz, Marlies and Angelberger, Marianne and Sirtl, Simon and Philipp, Alexander B and Rössler, Daniel and Ondrejkova, Katarina and Markwardt, Daniel and Heinrich, Kathrin and Westphalen, Christoph Benedikt and Heinemann, Volker and Jung, Andreas and Rogowski, Paul and Niyazi, Maximilian and Kleger, Alexander and Mayerle, Julia and Beyer, Georg and Beyer, Georg},
title = {Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report},
journal = {Oncology Research and Treatment},
year = {2025},
doi = {10.1159/000545975}
}
EUVIMED